Innovation Value Institute Analysis Demonstrates HeartSciences' MyoVista WavECG Potential to Improve Cardiovascular Pathway Efficiency
Innovation Value Institute Analysis Demonstrates HeartSciences' MyoVista WavECG Potential to Improve Cardiovascular Pathway Efficiency
Southlake, TX, July 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced an analysis published by the Innovation Value Institute (IVI) titled "Introduction of AI assisted Digital Health Technology to Improve Cardiovascular Pathway Efficiency" focused on the MyoVista wavECG's potential to radically improve the cardiovascular pathway efficiency.
2024年7月26日,德克薩斯州Southlake(環球新聞)-- 醫心科技有限公司,註冊商號爲Heart Test Laboratories, Inc.,證券代碼爲納斯達克: HSCS;HSCSW,又稱HeartSciences(下稱「本公司」)是一家以人工智能爲核心的醫療科技公司,專注於通過對心臟疾病的早期檢測來挽救生命,致力於將ECG(又稱爲EKG)變得更加有臨床價值。每週有數百萬份ECG檢查,該公司的宗旨是通過使其成爲更有價值的心臟篩查工具,特別是在前線或臨床現場,改善醫療保健。HeartSciences擁有最大的人工智能-ECG算法庫之一,正在開發可在硬體無關的基於雲的平台上或其專有的MyoVista wavECG設備上提供的AI-ECG解決方案,以幫助全球各種醫療機構在合適的環境下診斷心血管疾病。HeartSciences的FDA覈准申請的第一項產品候選人MyoVista wavECG(簡稱MyoVista)是一項靜息狀態的12導聯心電圖,也旨在提供傳統的心電圖信息,並在同一檢查中提供與心臟功能障礙相關的診斷信息,這在傳統上只能通過使用心臟成像技術獲得。HeartSciences (納斯達克:HSCS;HSCSW)(下稱公司)是一家人工智能(AI)醫療科技公司,專注於通過早期檢測心臟病來挽救生命,今天宣佈創新價值研究所(IVI)發佈的一份名爲「引入AI輔助數字健康技術以提高心血管通路效率」的分析報告專注於MyoVista wavECG潛力以徹底改善心血管通路效率。
Founded in 2006, the Maynooth University, Ireland based IVI is a multidisciplinary research institute focused on digital transformation and technology adoption. The paper analyzed the potential impact of using the MyoVista wavECG for prescreening of patients being considered for an echocardiographic examination related to left ventricle (LV) function at a National Health Service (NHS) district general hospital. The paper noted that "analysis of the audited figures show that 49.5% of the LV function test queries could potentially be eliminated from the waitlist."
創立於2006年的愛爾蘭梅納斯大學(IVI)是一個專注於數字化轉型和技術應用的多學科研究機構。該報告分析了使用MyoVista wavECG對接受與左心室(LV)功能相關的超聲心動圖檢查考慮的患者進行預先篩查對全國醫療服務體系(NHS)地區綜合醫院心血管病治療效率的潛在影響。報告指出,「審計數字分析表明,49.5%的LV功能測試查詢有可能被取消等待名單。」
Duncan Sleeman, UWE - Senior Lecturer (Cardiac Physiology) / Programme Lead (PGCert Echocardiography), an author of the abstract, stated, "The introduction of the MyoVista wavECG device could revolutionize our approach to managing the LV function query echo referral waitlist. By pre-screening in-hospital patients with this AI-powered ECG device, we could identify those who do not require further cardiology intervention, thereby reducing unnecessary referrals and enabling quicker access to care for those in need."
UWE的Duncan Sleeman高級講師(心臟生理學)/ 項目負責人(PGCert超聲心動圖學)作爲一篇摘要的作者,指出:“引入MyoVista wavECG設備可能徹底改變我們管理LV功能查詢回聲轉診等待名單的方法。 通過使用這種AI驅動的ECG設備預篩住院患者,我們可以識別不需要進一步心臟病學干預的患者,從而減少不必要的轉診,並使需要幫助的患者更快獲得護理。
Andrew Simpson, CEO of HeartSciences, said, "Along with improving patient care, one of the key goals for our AI-ECG technology is improving the efficiency of the cardiovascular care pathway. This analysis by the IVI demonstrates that our technology has the potential to do just that. We look forward to bringing this valuable technology to market."
HeartSciences公司的首席執行官安德魯·辛普森(Andrew Simpson)表示:「除了改善患者護理外,我們AI-ECG技術的一個主要目標是提高心血管護理路徑的效率。IVI的這一分析表明,我們的技術有潛力實現這一目標。我們期待將這一有價值的技術引入市場。」
The full abstract can be found here.
完整的摘要可在發表於IVI網站的創新價值研究所(Introduction of AI assisted Digital Health Technology to Improve Cardiovascular Pathway Efficiency)專欄中找到。這裏.
About HeartSciences
關於醫心科技公司
Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers. HeartSciences' first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test.
Heart Test Laboratories,Inc.,即HeartSciences,是一家醫療科技公司,專注於將創新的基於人工智能技術應用於心電圖(也稱爲心電圖),以擴展和改善心電圖的臨床效用。每週進行數百萬次心電圖檢查,公司的目標是通過使其成爲一個更有價值的心臟篩查工具,特別是在一線或基層臨床環境中,來改善醫療保健。HeartSciences擁有最大的人工智能心電圖算法庫之一,並正在開發AI-ECG解決方案,可在硬件不可知的基於雲的平台或其專有的MyoVista wavECG設備上提供,以幫助在全球任何護理環境中以最適合不同醫護人員的方式識別心血管疾病。HeartSciences的FDA清除首個產品候選人,即MyoVista wavECG或MyoVista,是一款休息12導聯心電圖,旨在提供與心臟功能障礙相關的診斷信息,這些信息傳統上僅能通過心臟成像來獲得。MyoVista還提供同一測試中的常規心電圖信息。
For more information, please visit: . X: @HeartSciences
更多信息,請訪問:@HeartSciences X。
Safe Harbor Statement
Safe Harbor聲明
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' Annual Report on Form 10-K for the fiscal year ended April 30, 2023, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 18, 2023, HeartSciences' Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2024, filed with the SEC on March 14, 2024 and in HeartSciences' other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
此公告包含根據1933年修改的證券法第27(A)節和1934年修改的證券交易法第21(E)節的前瞻性聲明。這些前瞻性聲明是根據1995年私人證券訴訟改革法案的"安全港"規定作出的,並涉及公司未來的財務和營運表現。除歷史事實陳述外,本文所載內容包括但不限於有關HeartSciences信仰和期望的聲明。這些聲明基於當前的期望、假設和涉及關於未來經濟、競爭和市場狀況以及未來經營決策的判斷等方面的不確定性,所有這些都難以或不可能準確預測,並且其中許多都不在公司的控制之內。這些前瞻性聲明中反映的期望涉及重大的假設、風險和不確定性,而這些期望可能被證明是不正確的。投資者不應過度依賴這些前瞻性聲明,這些聲明僅在本新聞稿發佈之日有效。潛在的風險和不確定性包括但不限於,HeartSciences2013財年報告文件Form 10-k中討論的風險,該文件於2018年6月18日提交給美國證券交易委員會(SEC)。HeartSciences2013財年第三季度報告文件Form 10-Q,於2018年3月14日提交給SEC。以及HeartSciences在www.sec.gov提交的其他文件。除證券法規定的向證券法律規定的部門報告之外,公司不承擔更新這些前瞻性聲明的義務。
Contacts:
聯繫人:
HeartSciences
Gene Gephart
+1-682-244-2578 (US)
info@heartsciences.com
HeartSciences
Gene Gephart
+1-682-244-2578(美國)
info@heartsciences.com
Investors
Gilmartin Group
Vivian Cervantes
investorrelations@heartsciences.com
投資者
吉爾馬汀集團
Vivian Cervantes
investorrelations@heartsciences.com